Interferon alfa-2a and fluorouracil in the treatment of patients with advanced esophageal cancer Journal Article

  

Authors:	Kelsen, D.; Lovett, D.; Wong, J.; Saltz, L.; Buckley, M.; Murray, P.; Heelan, R.; Lightdale, C.
Article Title:	Interferon alfa-2a and fluorouracil in the treatment of patients with advanced esophageal cancer
Abstract:	Purpose: The trial was undertaken to determine the response rate to and toxicities from the combination of interferon alfa-2a (IFN) and fluorouracil (FU) in patients with advanced esophageal cancer. Materials and Methods: In this prospective phase II trial conducted at a large tertiary referral cancer center and university hospital, 40 patients with advanced locoregional, metastatic epidermoid, or adenocarcinoma of the esophagus were given FU 750 mg/m2 by 24-hour continuous intravenous infusion days 1 to 5, followed by weekly outpatient bolus FU 750 mg/m2 and IFN 9 × 106 U three times per week from day 1. Dose was attenuated for fatigue, neurotoxicity, gastrointestinal toxicity, and myelosuppression. Results: Complete and partial responses were seen in 10 of 37 assessable patients with esophageal cancer (27%; 95% confidence interval, 0.13 to 0.41). Although substantial, toxicity was tolerable and primarily involved fatigue and mild myelosuppression. The median duration of response was 6.4 months (range, 2.8 to 14+ months). Conclusion: The combination of IFN and FU is an active regimen in the treatment of advanced esophageal cancer with a response rate similar to that reported for cisplatin-containing combinations in similar patient populations. Further studies based on this combination are indicated. © 1992 by American Society of Clinical Oncology.
Keywords:	adult; clinical article; aged; survival analysis; fatigue; carcinoma, squamous cell; fluorouracil; prospective studies; adenocarcinoma; phase 2 clinical trial; bone marrow suppression; antineoplastic combined chemotherapy protocols; drug administration schedule; alpha2a interferon; esophagus carcinoma; esophageal neoplasms; intravenous drug administration; middle age; recombinant alpha2a interferon; drug evaluation; interferon alfa-2a; human; male; female; priority journal; article; support, non-u.s. gov't
Journal Title:	Journal of Clinical Oncology
Volume:	10
Issue:	2
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	1992-02-01
Start Page:	269
End Page:	274
Language:	English
DOI:	10.1200/jco.1992.10.2.269
PUBMED:	1732428
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-0026599141&doi=10.1200%2fJCO.1992.10.2.269&partnerID=40&md5=c617da46b4f260c5337a2fed97cbd943
Notes:	Article -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/149836